Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 10, 2008, Pages 3939-3944

  Hao, Zhengrong ^a   Huang, Yan ^a   Cleman, Jake ^a   Jovin, Ion S ^a   Vale, Wylie W ^b   Bale, Tracy L ^c   Giordano, Frank J ^a  

^a YALE UNIVERSITY   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anti angiogenic; Cancer; CRF; CRFR2; Peptide

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; LIGAND; UROCORTIN II; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 2; UNCLASSIFIED DRUG; UROCORTIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

MUS;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; UROCORTINS;

EID: 41649112581     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712366105     Document Type: Article

References (29)

1. Bale TL (2006) Stress sensitivity and the development of affective disorders. Horm Behav 50:529-533.
2. Bale TL, et al. (2002) Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 99:7734-7739.
3. Bale TL (2005) Sensitivity to stress: Dysregulation of CRF pathways and disease development. Horm Behav 48:1-10.
4. Fekete EM, Zorrilla EP (2007) Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: Ancient CRF paralogs. Front Neuroendocrinol 28:1-27.
5. Bale TL, et al. (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24:410-414.
6. Bale TL, Anderson KR, Roberts AJ, Lee KF, Nagy TR, Vale WW (2003) Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 144:2580-2587.
7. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, Spiess J (2000)Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419.
8. Bale TL, et al. (2004) The cardiovascular physiologic actions of urocortin II: Acute effects in murine heart failure. Proc Natl Acad Sci USA 101:3697-3702.
9. Coste SC, et al. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24:403-409.
10. Wiley KE, Davenport AP (2004) CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 143:508-514.
11. Leitch IM, et al. (1998) Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro. J Clin Endocrinol Metab 83:4510-4513.
12. Davis ME, et al. Urocortin 2 infusion in human heart failure. (2007) Eur Heart J 28:2589-2597.
13. Huang Y, et al. (2002) Urocortin-induced endothelium-dependent relaxation of rat coronary artery: Role of nitric oxide and K+ channels. Br J Pharmacol 135:1467-1476.
14. 2+- activated K+ channels in endothelium-independent relaxation by urocortin in the rat coronary artery. Cardiovasc Res 57:824-833.
15. Davis ME, et al. (2007) Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol 49:461-471.
16. Krause K, Schnitger A, Fimmel S, Glass E, Zouboulis CC (2007) Corticotropin-releasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands. Horm Metab Res 39:166-170.
17. Graziani G, et al. (2002) CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143:807-813.
18. Carlson KW, et al. (2001) Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res 21:1173-1179.
19. Wang J, Li S (2007) Corticotropin-releasing factor family and its receptors: tumor therapeutic targets? Biochem Biophys Res Commun 362:785-788.
20. Tache Y, Perdue MH (2004) Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil 16(Suppl 1):137-142.
21. Wu Y, Xu Y, Zhou H, Tao J, Li S (2006) Expression of urocortin in rat lung and its effect on pulmonary vascular permeability. J Endocrinol 189:167-178.
22. Slominski AT, et al. (2000) Corticotropin releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes. In Vitro Cell Dev Biol Anim 36:211-216.
23. Zbytek B, Slominski AT (2005) Corticotropin-releasing hormone induces keratinocyte differentiation in the adult human epidermis. J Cell Physiol 203:118-126.
24. Davidson SM, et al. (2005) The transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells but is specific to the hypertrophic effect of urocortin. ChemBioChem 6:162-170.
25. Singh LK, et al. (1999) Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J Pharmacol Exp Ther 288:1349-1356.
26. Moss AC, et al. (2007) Urocortin II mediates proinflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut 56:1210-1217.
27. Kim S, Bakre M, Yin H, Varner JA (2002) Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 110:933-941.
28. Lei L, et al. (2007) Endothelial expression of beta-1 integrin is required for embryonic vascular patterning and postnatal vascular remodeling. (2008) Mol Cell Biol 28:794-802.
29. Netherton SJ, Sutton JA, Wilson LS, Carter RL, Maurice DH (2007) Both protein kinase A, exchange protein activated by cAMP coordinate adhesion of human vascular endothelial cells. Circ Res 101:768-776.